People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

said both Wegovy and Zepbound have demonstrated clinically significant weight reduction in clinical trial programs. The statement also said, in part, that "robust data" supporting Wegovy's ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

Participants taking Zepbound lost more weight and more inches off their waistline than those taking Wegovy. People taking Zepbound lost nearly 50% more weight than those on Wegovy. Now ...